Catabasis Pharma To Present CAT-1004 Data From Part A Of The MoveDMD Trial At The 2016 Muscular Dystrophy Association Clinical Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data from Part A of the MoveDMD trial of CAT-1004 for Duchenne muscular dystrophy (DMD) at the 2016 Muscular Dystrophy Association Clinical Conference held March 20 – 23, 2016, in Arlington, VA, at the Hyatt Regency Crystal City.